	US 12,227,754 B2
	Adenoviral expression vector and methods and cell lines for production
Colin Exline, San Diego, CA (US); Huizhu Liu, San Deigo, CA (US); and Sean Stevens, Del Mar, CA (US)
Assigned to Lung Biotechnology PBC, Silver Spring, MD (US)
Filed by Lung Biotechnology PBC, Silver Spring, MD (US)
Filed on Apr. 6, 2021, as Appl. No. 17/223,785.
Claims priority of provisional application 63/006,266, filed on Apr. 7, 2020.
Prior Publication US 2021/0310025 A1, Oct. 7, 2021
Int. Cl. C12N 15/86 (2006.01); C07K 14/54 (2006.01); C12N 15/10 (2006.01)

CPC C12N 15/86 (2013.01) [C07K 14/5428 (2013.01); C12N 15/102 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10051 (2013.01); C12N 2830/001 (2013.01); C12N 2830/50 (2013.01)]

7 Claims

1. A non-replicating adenovirus expression vector comprising:

a) one or more mutations that render the adenovirus replication incompetent; and

b) at least one nucleotide sequence encoding a gene product,

wherein the vector comprises a nucleotide sequence having at least 95% sequence identity over the entire sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the entire complementary sequence thereto.